

Date: 08/11/2023

To
BSE Limited,
Dept. of Corporate Services,
Floor 25, PJ Towers, Dalal Street,
Mumbai- 400001.

Scrip Code: 526445

Dear Sir/Madam,

Sub: Intimation of Board Meeting under Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 29(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to intimate that, in accordance with Regulation 33(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, meeting of the Board of Directors will be held on Tuesday, November 14, 2023 inter alia, to consider and approve the following:

- The Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter & half year ended September 30, 2023, along with the Limited Review Report of Statutory Auditor.
- Any other business with the permission of the Chair.

In accordance with the Company's Code of Conduct to regulate, monitor and report trading by insiders, adopted by the Board pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the securities of the Company is closed for the designated persons from October 01, 2023, till 48 hours after the announcement of financial results i.e., up to November 16, 2023 (both days inclusive).

This is for your information and record.

Thanking You,

Yours Faithfully,

For **Indrayani Biotech Limited**

Rajesh Kumar Sundarray
Company Secretary & Compliance Officer

Encl: As above